Detection of Genetic Mutations by Next-Generation Sequencing for Predicting Prognosis of Extensive-Stage Small-Cell Lung Cancer
Some studies have revealed that specific genetic mutations could be associated with chemotherapy response or even survival in small-cell lung cancer (SCLC). Our retrospective study aimed to identify the correlation between genetic mutations and progression-free survival (PFS) in extensive-stage SCLC...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2020-01-01
|
Series: | Journal of Oncology |
Online Access: | http://dx.doi.org/10.1155/2020/8811487 |
id |
doaj-15762b0ce061475c8d5ee9c4f679c6bd |
---|---|
record_format |
Article |
spelling |
doaj-15762b0ce061475c8d5ee9c4f679c6bd2020-11-30T09:11:27ZengHindawi LimitedJournal of Oncology1687-84501687-84692020-01-01202010.1155/2020/88114878811487Detection of Genetic Mutations by Next-Generation Sequencing for Predicting Prognosis of Extensive-Stage Small-Cell Lung CancerDongfang Chen0Jianlin Xu1Rong Qiao2Yizhuo Zhao3Tianqing Chu4Baohui Han5Runbo Zhong6Department of Pulmonary Medicine, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, ChinaDepartment of Pulmonary Medicine, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, ChinaDepartment of Pulmonary Medicine, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, ChinaDepartment of Pulmonary Medicine, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, ChinaDepartment of Pulmonary Medicine, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, ChinaDepartment of Pulmonary Medicine, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, ChinaDepartment of Pulmonary Medicine, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, ChinaSome studies have revealed that specific genetic mutations could be associated with chemotherapy response or even survival in small-cell lung cancer (SCLC). Our retrospective study aimed to identify the correlation between genetic mutations and progression-free survival (PFS) in extensive-stage SCLC after first-line chemotherapy. A total of 75 patients with extensive-stage SCLC confirmed by histopathology from February 2018 to February 2019 were retrospectively analyzed. The biopsy specimens of all patients were analyzed by Next-Generation Sequencing (NGS). All patients received first-line chemotherapy and follow-up at Shanghai Chest Hospital. Eleven genes were mutated in, at least, 10% of the 75 patients, including TP53 (96%), RB1 (77%), SMAD4 (32%), NOTCH1 (21%), PTEN (16%), FGFR1 (16%), KDR (15%), PIK3CA (15%), ROS1 (15%), BRCA2 (13%), and ERBB4 (10%). The median number of mutated genes among all patients was 5. Patients with more than 5 mutated genes (PFS = 6.7 months, P=0.004), mutant TP53 (PFS = 5.0 months, P=0.011), and mutant BRCA2 (PFS = 6.7 months, P=0.046) had better PFS after first-line chemotherapy than other patients. Multivariate Cox regression analysis showed that patients who achieved a PR (HR 3.729, 95% CI 2.038–6.822), had more than 5 mutated genes (HR 1.929, 95% CI 1.096–3.396), had BRCA2 mutations (HR 4.581, 95% CI 1.721–12.195), and had no liver metastasis (HR 0.415, 95% CI 0.181–0.951) showed improvements in PFS after first-line chemotherapy. In conclusion, the number of mutated genes and BRCA2 mutation status in extensive-stage SCLC were significantly related to PFS after first-line chemotherapy.http://dx.doi.org/10.1155/2020/8811487 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Dongfang Chen Jianlin Xu Rong Qiao Yizhuo Zhao Tianqing Chu Baohui Han Runbo Zhong |
spellingShingle |
Dongfang Chen Jianlin Xu Rong Qiao Yizhuo Zhao Tianqing Chu Baohui Han Runbo Zhong Detection of Genetic Mutations by Next-Generation Sequencing for Predicting Prognosis of Extensive-Stage Small-Cell Lung Cancer Journal of Oncology |
author_facet |
Dongfang Chen Jianlin Xu Rong Qiao Yizhuo Zhao Tianqing Chu Baohui Han Runbo Zhong |
author_sort |
Dongfang Chen |
title |
Detection of Genetic Mutations by Next-Generation Sequencing for Predicting Prognosis of Extensive-Stage Small-Cell Lung Cancer |
title_short |
Detection of Genetic Mutations by Next-Generation Sequencing for Predicting Prognosis of Extensive-Stage Small-Cell Lung Cancer |
title_full |
Detection of Genetic Mutations by Next-Generation Sequencing for Predicting Prognosis of Extensive-Stage Small-Cell Lung Cancer |
title_fullStr |
Detection of Genetic Mutations by Next-Generation Sequencing for Predicting Prognosis of Extensive-Stage Small-Cell Lung Cancer |
title_full_unstemmed |
Detection of Genetic Mutations by Next-Generation Sequencing for Predicting Prognosis of Extensive-Stage Small-Cell Lung Cancer |
title_sort |
detection of genetic mutations by next-generation sequencing for predicting prognosis of extensive-stage small-cell lung cancer |
publisher |
Hindawi Limited |
series |
Journal of Oncology |
issn |
1687-8450 1687-8469 |
publishDate |
2020-01-01 |
description |
Some studies have revealed that specific genetic mutations could be associated with chemotherapy response or even survival in small-cell lung cancer (SCLC). Our retrospective study aimed to identify the correlation between genetic mutations and progression-free survival (PFS) in extensive-stage SCLC after first-line chemotherapy. A total of 75 patients with extensive-stage SCLC confirmed by histopathology from February 2018 to February 2019 were retrospectively analyzed. The biopsy specimens of all patients were analyzed by Next-Generation Sequencing (NGS). All patients received first-line chemotherapy and follow-up at Shanghai Chest Hospital. Eleven genes were mutated in, at least, 10% of the 75 patients, including TP53 (96%), RB1 (77%), SMAD4 (32%), NOTCH1 (21%), PTEN (16%), FGFR1 (16%), KDR (15%), PIK3CA (15%), ROS1 (15%), BRCA2 (13%), and ERBB4 (10%). The median number of mutated genes among all patients was 5. Patients with more than 5 mutated genes (PFS = 6.7 months, P=0.004), mutant TP53 (PFS = 5.0 months, P=0.011), and mutant BRCA2 (PFS = 6.7 months, P=0.046) had better PFS after first-line chemotherapy than other patients. Multivariate Cox regression analysis showed that patients who achieved a PR (HR 3.729, 95% CI 2.038–6.822), had more than 5 mutated genes (HR 1.929, 95% CI 1.096–3.396), had BRCA2 mutations (HR 4.581, 95% CI 1.721–12.195), and had no liver metastasis (HR 0.415, 95% CI 0.181–0.951) showed improvements in PFS after first-line chemotherapy. In conclusion, the number of mutated genes and BRCA2 mutation status in extensive-stage SCLC were significantly related to PFS after first-line chemotherapy. |
url |
http://dx.doi.org/10.1155/2020/8811487 |
work_keys_str_mv |
AT dongfangchen detectionofgeneticmutationsbynextgenerationsequencingforpredictingprognosisofextensivestagesmallcelllungcancer AT jianlinxu detectionofgeneticmutationsbynextgenerationsequencingforpredictingprognosisofextensivestagesmallcelllungcancer AT rongqiao detectionofgeneticmutationsbynextgenerationsequencingforpredictingprognosisofextensivestagesmallcelllungcancer AT yizhuozhao detectionofgeneticmutationsbynextgenerationsequencingforpredictingprognosisofextensivestagesmallcelllungcancer AT tianqingchu detectionofgeneticmutationsbynextgenerationsequencingforpredictingprognosisofextensivestagesmallcelllungcancer AT baohuihan detectionofgeneticmutationsbynextgenerationsequencingforpredictingprognosisofextensivestagesmallcelllungcancer AT runbozhong detectionofgeneticmutationsbynextgenerationsequencingforpredictingprognosisofextensivestagesmallcelllungcancer |
_version_ |
1715027884964315136 |